Claims for Patent: 8,475,822

Summary for Patent: 8,475,822

Title:	Room temperature-curable polymers
Abstract:	Methods of making room temperature-curable polymers. Reactants include siloxane-terminated polymers and silanols. The reactants are mixed, and the polymerization allowed to proceed in air at room temperature. The polymers are exceptionally useful because they allow for the incorporation into the polymers themselves of one or more therapeutic compounds. Thus, medical devices from which controlled drug release is desirable (for either local or systemic delivery) can be coated with therapeutic compound-containing polymers of the invention. In a preferred embodiment, a polymer of poly(MPC.sub.w:LAM.sub.x:HPMA.sub.y:TSMA.sub.z) where w, x, y, and z represent the molar ratios of monomers used in the feed for preparing the polymer; MPC represents the unit 2-methacryoyloxyethylphosphorylcholine, LMA represents the unit lauryl methacrylate, HPMA represents the unit 2-hydroxypropyl methacrylate, and TSMA represents the unit 3-trimethoxysilylpropyl methacrylate is reacted with polydimethylsiloxane. In another preferred embodiment, a therapeutic compound is incorporated into the polymer, such as dexamethasone.
Inventor(s):	Hauenstein; Dale E. (Gurnee, IL)
Assignee:	Abbott Laboratories (Abbott Park, IL)
Application Number:	13/019,556
Patent Claims:	1. A method of coating a medical device, comprising preparing a composition which comprises at least one therapeutic compound and a molecule of formula IV: ##STR00010## wherein the preparing step comprises reacting a molecule of formula I: ##STR00011## with a molecule of formula II: ##STR00012## adding the therapeutic compound to reactant of formula I or reactant of formula II or both prior to the reaction thereof, or adding the therapeutic compound to the reaction mixture of the reactants during the reaction thereof; wherein R.sub.1 comprises a polymer, the polymer is in part polycarboxylic acid, cellulosic polymer, gelatin, polyvinylpyrrolidone, maleic anhydride polymer, polyamide, polyvinyl alcohol, polyethylene oxide, glycosaminoglycan, polysaccharide, polyester, silicone, polyurethane, polyorthoester, polyanhydride, polycarbonate, polypropylenes, polylactic acid, polyglycolic acid, polycaprolactone, polyhydroxybutyrate valerate, polyacrylamide, polyether, and a mixture and copolymer thereof; R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6 and R.sub.7 are alkyls or silanol-terminated alkyls; wherein n is an integer, 1.ltoreq.n.ltoreq.100; wherein the reaction is carried out at a temperature compatible with the therapeutic compound; and applying the composition to the surface of the medical device. 2. The method of claim 1, wherein the temperature, T, at which the reaction is carried out is 4.degree. C..ltoreq.T.ltoreq.100.degree. C. 3. The method of claim 2, wherein 15.degree. C..ltoreq.T.ltoreq.30.degree. C. 4. The method of claim 2, wherein 20.degree. C..ltoreq.T.ltoreq.22.degree. C. 5. The method of claim 1, wherein the therapeutic compound is one selected from the group consisting of paclitaxel, sirolimus, zotarolimus, esters and salts thereof. 6. The method of claim 1, wherein the therapeutic compound comprises one selected from the group consisting of anti-proliferative agents, anti-platelet agents, anti-inflammatory agents, anti-thrombotic agents and thrombolytic agents. 7. The method of claim 6, wherein the anti-inflammatory agent is one selected from the group consisting of dexamethasone, hydrocortisone, estradiol, acetaminophen, ibuprofen, naproxen, fluticasone, clobetasol, adalimumab and sulindac. 8. The method of claim 6, wherein the therapeutic compound comprises an antibody. 9. The method of claim 6, wherein the therapeutic compound comprises dexamethasone. 10. The method of claim 1, wherein the medical device comprises a stent. 11. The method of claim 1, wherein the composition comprises at least two therapeutic compounds, a first compound comprising zotarolimus or paclitaxel, and a second compound selected from the group consisting of anti-proliferative agents, anti-platelet agents, anti-inflammatory agents, anti-thrombotic agents and thrombolytic agents. 12. The method of claim 1, wherein R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6 and R.sub.7 are methyl groups.

Details for Patent 8,475,822

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	12/31/2002		2025-12-21
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	02/21/2008		2025-12-21
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	04/24/2013		2025-12-21
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	09/23/2014		2025-12-21
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	11/23/2015		2025-12-21
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	03/09/2016		2025-12-21